A New Era for Chronic Hand Eczema: FDA Approval of Anzupgo® Signals Paradigm Shift in Treatment Standards
In a landmark decision that’s poised to transform chronic hand eczema (CHE) management, the U.S. Food and Drug Administration (FDA) has approved delgocitinib cream 2%, making it the first and only therapy specifically indicated for moderate-to-severe CHE in adults. For clinicians and dermatology leaders, this approval represents more than a new tool in the therapeutic […]
Epidermolysis Bullosa: The Importance of an Efficient Diagnosis
What is EB? Dermatologists know that Epidermolysis Bullosa (EB), is a family of rare genetic disorders characterized by blistering and fragility of the skin and mucous membranes that can affect the mouth, esophagus, lungs, nails, and other areas of the body. This serious condition requires efficient diagnosis but sadly, there is currently no known cure. […]
